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AbstrAct
Introduction Disorders of fetal growth, such as 
intrauterine growth restriction (IUGR) and large for 
gestational age (LGA), have been found to have a profound 
effect on the development of the fetal kidney. Abnormal 
kidney development is associated with hypertension and 
chronic kidney disease later in life. This study will use 
a novel ultrasound measurement to assess the renal 
parenchymal growth and kidney arterial blood flow in the 
fetus to evaluate the development of the fetal kidneys 
and provide an indirect estimate of nephron number. 
Measurements in normally grown, IUGR and LGA fetuses 
will be compared to determine if changes in renal 
parenchymal growth can be detected in utero.
Methods and analysis This longitudinal, prospective, 
observational study will be conducted over 12 months 
in the Ultrasound Department of the Townsville Hospital, 
Australia. The study will compare fetal renal parenchymal 
thickness (RPT) and renal artery Doppler flow between 
IUGR fetuses and appropriately grown fetuses, and LGA 
fetuses and appropriately grown fetuses between 16 
and 40 weeks. The fetal RPT to renal volume ratio will 
also be compared, and correlations between RPT, renal 
parenchymal echogenicity, fetal Doppler indices and 
amniotic fluid levels will be analysed.
Ethics and dissemination This study was approved by 
the Townsville Health District Human Research Ethics 
Committee. The study results will form part of a thesis 
and will be published in peer-reviewed journals and 
disseminated at international conferences.
IntroductIon
Chronic kidney disease is an increasing 
contributor to the global burden of disease, 
with hypertension now the leading risk 
factor.1 Recognition of the risk factors and 
implementation of preventive strategies is 
crucial to reducing hypertension and kidney 
disease. Abnormalities in fetal growth, such as 
intrauterine growth restriction (IUGR), have 
a profound effect on the kidney develop-
ment.2 3 The association between an adverse 
intrauterine environment and chronic kidney 
disease later in life is now compelling.4–6 
During early fetal life, there is transient 
development and regression of the primary 
(pronephros) and secondary (mesonephros) 
fetal kidneys between day 23 and day 112 of 
embryonic life.7 The permanent functional 
tertiary fetal kidney is the metanephros which 
begins developing on day 30.7 Nephrogenesis 
involves the formation of the functional units 
of the kidney called nephrons and continues 
up to 36 weeks’ gestational age.8 9 It is essential 
that appropriate nephrogenesis is achieved in 
utero as the number and quality of nephrons 
directly influences lifetime kidney function.10
IUGR can result in a significant reduc-
tion in nephron number; however, large for 
gestational age (LGA), particularly related to 
maternal hyperglycaemia, is also associated 
with abnormal fetal kidney development and 
an increased risk of hypertension and chronic 
kidney disease.11 A better understanding 
of the relationship between abnormal 
fetal growth and nephrogenesis is needed. 
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Protocol
strengths and limitations of this study
 ► This will be the first study to use a novel ultrasound 
measurement of the fetal renal parenchyma and 
measurements of renal blood flow to assess fetal 
kidney growth.
 ► Fetal kidney growth will be assessed not only in 
normally grown but also in growth-restricted and 
large-for-gestational-age fetuses.
 ► This is a prospective, longitudinal, rather than cross-
sectional, ultrasound study and should enhance our 
understanding of how fetal kidneys grow.
 ► This study is the first of a series of studies 
investigating kidney growth, and although renal 
function and renal parenchymal thickness of the 
infants are not included in this study, follow-up of 
the infants will be included in future studies.
 ► Due to fetal position and/or maternal habitus, not all 
kidney measurements may be obtainable at every 
scan.
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Figure 1 Measurement of kidney length (1) and the anterior 
(2) and posterior (3) fetal renal parenchymal thickness from 
the inner aspect of the renal capsule to the sinus–pyramidal 
apex interface.
Presently, the only accurate method of calculating human 
nephron number is during an autopsy.12 A non-invasive 
measure of nephron endowment is needed.
Ultrasound is the primary imaging modality for evalu-
ating fetal kidneys. We conducted a systematic review on 
the evaluation of fetal kidney growth using ultrasound 
which revealed that there are few good-quality, longitu-
dinal studies.13 The most commonly reported ultrasound 
measurement was renal length; however, renal length 
alone was not found to be very sensitive to evaluate disrup-
tions in fetal kidney growth in the presence of fetal growth 
restriction.13 Few studies analysed the effects of IUGR on 
fetal kidney growth, and no studies have, to date, analysed 
if LGA has an effect on fetal kidney growth. Results from 
two-dimensional (2D) and three-dimensional (3D) renal 
volume (RV) calculations were disappointing. Volumes 
calculated from 2D measurements underestimate RVs by 
as much as 24%.14 Substantial variations were reported 
for ‘normal’ 3D kidney volumes, and good reliability 
and reproducibility has not yet been demonstrated. 
Currently, there is no easily repeatable, sensitive method 
of measuring changes in fetal kidney growth.13
Measuring the renal parenchyma with ultrasound is 
a novel method to assess fetal kidney development and 
predict future renal function. Measuring just the renal 
parenchyma will measure only the important func-
tional part of the kidney which contains the nephrons 
(figure 1). One small cross-sectional study measured fetal 
renal parenchyma in normally grown fetuses15; however, 
no studies have evaluated the fetal renal parenchyma in 
abnormally grown fetuses. Preliminary data from term 
neonates16 and children17 indicate that the parenchymal 
thickness may be a more reliable investigative method 
to define normal and abnormal kidney development. 
Methods such as measuring the parenchymal thickness, 
RV to parenchymal thickness ratio, renal artery Dopplers 
and echogenicity of the renal parenchyma are potential 
non-invasive methods to evaluate nephron endowment 
and future renal function.
The aim of this study is to use ultrasound to assess the 
fetal renal parenchymal growth in a pregnant population 
demonstrating either normal or abnormal growth and 
determine if abnormal fetal growth influences fetal renal 
parenchymal thickness (RPT). Non-invasive ultrasound 
techniques are used. The results could help identify 
factors that adversely affect kidney development so that 
they could be modified by public health interventions 
and education programmes. This may promote improved 
fetal nephron number and quality at birth and reduce 
susceptibility to chronic disease in later life.
MEthods And AnAlysIs
objectives
Primary objectives
 ► Determine normal RPT of fetuses from 16 to 40 weeks’ 
gestation from a group of normally grown fetuses.
 ► Determine the effects of IUGR and LGA on RPT in a 
group of abnormally grown fetuses.
Secondary objectives
 ► Assess the relationship between RPT and renal artery, 
umbilical artery and middle cerebral artery Doppler 
indices, and amniotic fluid levels.
 ► Assess the relationship between renal parenchymal 
echogenicity, renal artery Doppler flow and IUGR or 
LGA.
study design and setting
This is a prospective, longitudinal, observational study 
being conducted over 12 months, commencing in May 
2017, in the Ultrasound Department of the Townsville 
Hospital, Australia.
Participants
Patients who are referred for a diagnostic second 
trimester ultrasound scan will be recruited for this study. 
Pregnant women of 18 years or older, with an accurately 
dated singleton pregnancy of 16 weeks’ gestation or 
more, will be included. Pregnant women with uncertain 
dates, multiple pregnancy or any known major congenital 
fetal abnormality or chromosomal fetal abnormality will 
be excluded.
recruitment and consent of participants
Pregnant patients 18 years of age or older, who present 
to the Medical Imaging Department at the Townsville 
Hospital for an obstetric ultrasound, will be invited to 
participate. In addition, mixed risk patients may also be 
informed about the study by their treating obstetrician, 
midwife or sonographer. Detailed written information 
will be given to the patient and written consent obtained.
study process
Figure 2 outlines the flow schedule of the participants. 
The first ultrasound scan will be performed from 16 
weeks and then follow-up ultrasounds will be performed 
at least every 4 weeks from the first ultrasound scan. Some 
women, particularly with high-risk pregnancies, will 
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Figure 2 Flow chart of study participants.
require more than one clinically indicated ultrasound. 
For example, women with a growth-restricted fetus may 
need to be monitored by ultrasound monthly or more 
frequently. However, the control group of healthy women, 
with appropriately grown fetuses, may only require one to 
two clinically indicated scans between 16 and 40 weeks’ 
gestation. To obtain good longitudinal data, particularly 
for the control group, the women will be asked to attend 
for additional research scans every 4 weeks until delivery.
ultrasound examinations
Australian Accredited Medical Sonographers with at 
least 2 years’ postultrasound qualification experience 
will perform all ultrasound examinations. A high-level 
ultrasound machine with pulse wave and colour Doppler 
flow will be used, and the highest frequency transducer 
possible, matching the mother’s body habitus, will be 
selected. When a woman attends for a clinically indicated 
scan, this will be the priority, and then the additional fetal 
renal measurements required for the research study will 
be performed thereafter.
Where possible, the fetal kidneys should be measured 
with the fetal spine up (anterior) or as close as possible to 
this position. The image is magnified so that the kidney 
occupies most of the image and both kidneys can be 
identified. A midsagittal scan of both kidneys along their 
longest length will be recorded and the longest length (L) 
of both kidneys measured. The parenchymal thickness 
will be measured in two directions: from the posterior 
aspect of the kidney to the pelvis (posterior parenchyma) 
and from the anterior border of the kidney to the pelvis 
(anterior parenchyma) (figure 1). A transverse section of 
the fetal abdomen at the level of each renal pelvis will 
be imaged. The maximum anteroposterior diameter (H) 
and transverse diameter (W) will be measured for both 
kidneys.
Bilateral fetal renal artery Dopplers will be performed 
in the coronal view of the kidneys. Colour flow should be 
used to identify the renal artery entering the kidney. A 
low wall filter of between 30 and 60 Hz will be used, and 
a sample gate of size 2–3 mm will be placed in the mid 
trunk of the renal artery. Using an angle as close to 0° as 
possible, a pulse wave signal will be obtained. The average 
of three consecutive waveforms will be used to calculate 
the resistivity index (RI) and pulsatility index (PI).
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Table 1 After baby’s birth, perinatal data to be collected 
from the mother and baby’s electronic medical record
Birth data to be 
collected
Onset of labour Gestational age 
at birth 
Antenatal steroids 
Mode of 
delivery
Birth weight Other antenatal 
medications
Placental 
histopathology
Gender Maternal medical 
history:
Apgar scores at 1 
and 5 min
 ► Diabetes
Umbilical artery 
cord potential 
hydrogen (pH)
 ► Renal disease
Base excess  ► Hypertension
Lactate Demographic, medical 
and obstetric history 
from participant 
questionnaire
The following routinely performed obstetric measure-
ments will also be recorded for the study:
 ► Single deepest pool amniotic fluid measurement;
 ► Umbilical artery Doppler;
 ► Middle cerebral artery Doppler (where clinically indi-
cated or 30 weeks’ gestation and over);
 ► Ductus venous, where clinically indicated;
 ► Biometries—head circumference (HC), biparietal 
diameter (BPD), abdominal circumference (AC), 
femur length (FL).
birth data
Outcome measures
Perinatal data will be collected from the mother and 
baby’s electronic medical record (table 1).
Primary outcome measure
 ► RPT: anterior and posterior thickness in longitudinal 
plane.
Secondary outcome measures
 ► RV: calculated using the formula 
RV=length×width×height×0.523;
 ► Fetal growth biometries: HC, BPD, AC and FL;
 ► Amniotic fluid: single deepest pool;
 ► Umbilical artery Doppler flow: RI and PI calcu-
lated from the average of at least three consecutive 
waveforms;
 ► Middle cerebral artery Doppler flow: RI and PI calcu-
lated from the average of at least three consecutive 
waveforms;
 ► Renal parenchymal echogenicity: subjectively assessed 
by the sonographer as either normal echogenicity, 
more hyperechoic than normal or more hypoechoic 
than normal;
 ► Renal artery Doppler flow: RI and PI calculated from 
the average of at least three consecutive waveforms.
sample size
Optimal sample size has been calculated based on a 
statistical power of 80% and a significance level of 0.05 
(two-tailed). Data from a previously published study16 
have demonstrated that the RPT was 9.4 mm (±1.1 mm) 
for normal birth weight neonates and 8.3 mm (±1.0 mm) 
for low birth weight neonates at term. Therefore, it is esti-
mated that a sample size of 45 will be needed (15 intra-
uterine growth-restricted fetuses, 15 LGA fetuses and 15 
appropriate for gestational age (AGA)). Allowing for 
the possibility of loss to follow-up, 20 participants will be 
recruited for each group resulting in a total of 60 partici-
pants, each having an ultrasound scan every 4 weeks.
data analysis
After the ultrasound examination is complete, and the 
baby is born, all data will be collated and divided into 
three groups: AGA, IUGR and LGA. Comparisons of 
RPT and renal artery Dopplers between IUGR and AGA 
fetuses, and LGA and AGA fetuses between 16 and 40 
weeks will be analysed. RV will be compared with RPT in 
each fetal group to obtain an RPT to RV ratio. Correla-
tion between RPT, renal parenchymal echogenicity, fetal 
Doppler indices and amniotic fluid levels will be carried 
out, and intraobserver and interobserver variability will 
be assessed.
Statistical analysis will be performed using IBM SPSS 
Statistics, V.24.0. The normality of the variables will be 
determined by the Kolmogorov-Smirnov test. Renal 
measurements will be expressed as means±SDs for 
continuous, normally distributed data and as a median 
(IQR) for continuous, non-normally distributed data. 
Paired/unpaired t-tests will be used to compare means 
of normally distributed data and Mann-Whitney or 
Kruskal-Wallis tests for non-normally distributed data. 
A value of P<0.05 will be considered statistically signifi-
cant. Univariate and multivariate analysis will be carried 
out to determine the association between RPT and 
other variables. Intraobserver variability will be deter-
mined by calculating the differences between the two 
measurements made by the same sonographer. Interob-
server variability will be assessed by calculating the 
differences between two measurements carried out on 
the same patient by different sonographers.
Data management
Data collection commenced in May 2017 and is planned 
to finish in December 2018 once the birth data of all 
participants are obtained. Participant data will be deiden-
tified and assigned a number code to ensure confidenti-
ality for each woman and baby.
Electronic data will be stored and saved on a pass-
word-protected computer. Hard (paper) copies of the 
consent form, questionnaire and data sheets from the 
ultrasound examination will be stored in a locked filing 
cabinet in the principal researcher’s office. This office 
is a secure room within the ultrasound department of 
the Townsville Hospital. Only the principal researcher 
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and members of the research team will have access to 
the data.
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